GLP-1 muscle loss: The hidden cost of weight loss without support

GLP-1 medications are helping millions of patients lose weight. But as adoption accelerates across employer and health plan populations, a new concern is emerging: what type of weight is being lost—and what it means for long-term health outcomes.

Lean muscle loss is not a cosmetic issue. It has serious implications for physical health, mobility, long-term function, and the cost of care. Research shows that sarcopenia can add nearly $900 in excess healthcare costs per employee annually. Muscle plays a critical role in maintaining strength, metabolic health, and physical resilience. When it declines, the risks extend well beyond weight loss itself.

GLP-1 medications are redefining how obesity is treated. Once used primarily to manage diabetes, drugs like semaglutide (Ozempic, Wegovy, and others) are now widely prescribed in weight-loss programs—particularly by employers and health plans seeking to improve metabolic health across their populations.

But as these programs scale, organizations are beginning to recognize that medication alone does not determine long-term outcomes. Weight loss achieved through GLP-1 therapy often depends on the daily behaviors that support cardiometabolic health, such as physical activity, nutrition, and long-term habit formation.

This guide explores the emerging risk of muscle loss during GLP-1 treatment and what employers and health plans should consider when designing sustainable weight-loss programs.

Why muscle loss during GLP-1 treatment matters

Lean muscle plays a critical role in maintaining mobility, metabolic health, and physical resilience. Loss of muscle during rapid weight reduction can create risks that extend well beyond body composition:

• Maintaining mobility and physical function
• Supporting metabolic health and glucose regulation
• Protecting against injury through strength and balance

Losing muscle during medically induced weight loss can contribute to sarcopenia, the progressive loss of muscle tissue and strength. GLP-1 medications can accelerate lean mass loss alongside fat loss. For individuals with low baseline muscle mass or limited physical activity, this can increase the risk of sarcopenia.

The implications extend beyond individual health outcomes. Declining muscle mass is associated with higher rates of injury, longer recovery periods, and increased downstream healthcare utilization.

Because of these risks, many organizations are beginning to look beyond medication access alone and consider how GLP-1 programs support long-term physical health. Maintaining muscle mass during weight loss often depends on daily behaviors such as physical activity, nutrition, and long term engagement with care.

The health and cost implications of muscle loss

Research highlights the broader impact of declining muscle mass, linking sarcopenia with:

• up to 33% of chronic pain cases in older adults
• a 60% higher risk of falls
• more than double the risk of disability in people with sarcopenic obesity

Significant lean muscle loss can compromise a person’s ability to function safely and independently. For employers and health plans supporting large GLP-1 populations, this raises important questions about how weight loss programs protect long term health outcomes.

GLP-1 weight loss includes lean muscle

GLP-1 medications reduce appetite and slow digestion, lowering calorie intake and often leading to rapid weight loss.

Rapid weight loss does not come from fat alone. Without interventions that help preserve lean mass, the body may break down both fat and muscle for energy. Clinical studies suggest that up to 39% of weight lost during GLP-1 treatment may come from lean mass, including muscle.

Fewer than 1 in 4 U.S. adults meet recommended physical activity levels. Many individuals starting GLP-1 treatment therefore begin with low muscle mass and limited physical conditioning. During rapid weight loss, lean muscle mass can decline quickly without strategies that help maintain strength and activity.

This creates an important clinical challenge. While weight loss occurs as intended, individuals may also become physically weaker and more metabolically vulnerable if lean muscle declines too rapidly.

The rebound weight gain challenge

One of the biggest concerns surrounding GLP-1 therapy is long-term sustainability. Many individuals struggle to maintain weight loss after stopping treatment.

• Up to 70% of GLP-1 users discontinue treatment within one year
• Up to two-thirds of lost weight may be regained within the first year after stopping medication

Muscle loss plays an important role in this cycle. Muscle tissue is metabolically active and contributes to the number of calories the body burns at rest. When muscle declines during weight loss, resting metabolic rate may also decrease. If medication is discontinued, individuals may burn fewer calories than before treatment, increasing the likelihood of weight regain.

This dynamic can create a challenging cycle:

Medication → muscle loss → weight regain → re-prescription

For employers and health plans, this dynamic can lead to ongoing pharmaceutical costs without corresponding improvements in long-term health outcomes.

The organizational cost of muscle loss

Muscle loss rarely appears as a formal diagnosis, but its impact is visible in workforce health outcomes:

• Rising MSK (musculoskeletal) claims
• Chronic pain, falls injuries, and fatigue-related disability
• Increased absenteeism and reduced productivity

These indirect outcomes are expensive. Sarcopenia is associated with $900 in excess healthcare costs per employee, per year, mostly tied to pain management, falls, and downstream care.

Physical inactivity adds another layer. It accounts for roughly 27% of total employee medical spend, much of it tied to preventable chronic conditions and injury-related care.

If GLP-1 users are losing lean mass and not adding structured support to their treatment plan, employers risk paying for short-term success with longer-term risk.

GLP-1 programs without support create financial risk

GLP-1 medications can produce meaningful weight loss. But without support that protects muscle and long-term health behaviors, the financial return may be limited.

• GLP-1s can cost up to $10,000 per member per year
• Projections for GLP-1s to make up 9% of total medical spend in some plans

This represents a significant investment. Without interventions that protect muscle mass and support long-term health behaviors, organizations may pay for temporary change without lasting return.

Movement is part of GLP-1 prescribing guidance. GLP-1 medications such as semaglutide are approved for weight management as an adjunct to a reduced-calorie diet and increased physical activity. In other words, medication is intended to be paired with lifestyle change.

Despite this guidance, many patients begin treatment without structured support for physical activity and strength-building, increasing the risk of lean-mass loss and weight regain.

Support healthier GLP-1 outcomes with structured wraparound care

Movement is part of the clinical guidance for GLP-1 medications, not just a lifestyle suggestion. Physical activity plays a critical role in:

• Preserving lean mass
• Supporting metabolic health and function
• Reducing mobility decline and fall risk
• Building habits that sustain outcomes beyond medication

Even modest levels of structured support can make a meaningful difference. The key is consistency and personalization, especially for populations starting from low baseline activity levels.

When employers treat lifestyle support as a wellness add-on, they miss the clinical and economic value it provides. When structured support is integrated into a broader GLP-1 strategy, organizations can help reduce avoidable musculoskeletal risk and support healthier long-term outcomes.

Managing GLP-1 populations at scale

As GLP-1 medications become more widely adopted, employers and health plans are beginning to look beyond medication access alone. Rapid weight loss can introduce new health considerations—including muscle loss, changes in physical function, and long-term weight maintenance challenges.

For organizations supporting large GLP-1 populations, the question is not only how to help members lose weight, but how to support lasting cardiometabolic health outcomes.

Many healthcare leaders are exploring more comprehensive approaches that help monitor emerging risks and support the daily behaviors that drive long-term health. This includes helping members stay active, maintain muscle mass, follow appropriate nutrition guidance, and remain engaged with their care between clinical visits.

Sword's Pulse, the cardiometabolic program within the AI Care Platform, provides continuous lifestyle support that complements traditional care. Pulse helps members stay engaged with the daily habits that improve cardiometabolic health.

For individuals using GLP-1 medications, this kind of continuous support can help reinforce the behaviors that protect lean mass, support metabolic health, and improve the likelihood that results are sustained over time.

Protect GLP-1 outcomes and long-term ROI

GLP-1 medications suppress appetite and slow digestion. But medication alone does not build strength, mobility, or long-term physical resilience.

GLP-1s can produce rapid weight loss, but without ongoing physical activity those results can be difficult to sustain. Studies show that up to two-thirds of weight lost may be regained within one year of stopping medication⁵ and when weight returns, it is often fat rather than lean muscle.

Supporting GLP-1 populations with structured wraparound care can help organizations protect both member outcomes and the value of their pharmaceutical investment.